 |
Top 10 Neurology startups in USA
Updated: May 09, 2024 |
1
Funding: $612M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
2
Funding: $544.8M
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases.
3
Funding: $307.3M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
4
Funding: $269.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
5
Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
6
Funding: $220.5M
Ceribell is focused on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective
Ceribell is focused on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective
7
Funding: $181.2M
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
8
Funding: $157.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
9
Funding: $115.1M
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases.
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases.
10
Funding: $109M
Nido Biosciences develops new precision medicines for neurological diseases and takes aim at Kennedy’s disease, a rare degenerative disorder.
Nido Biosciences develops new precision medicines for neurological diseases and takes aim at Kennedy’s disease, a rare degenerative disorder.
Ad
Advertise your startup
11
Funding: $101.5M
Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. Our product candidates utilize our proprietary Precisa development platform that are based on specific physical and chemical properties that enable targeted delivery to the exact site of the injury, and provide a controlled and sustained drug release to the affected area.
Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. Our product candidates utilize our proprietary Precisa development platform that are based on specific physical and chemical properties that enable targeted delivery to the exact site of the injury, and provide a controlled and sustained drug release to the affected area.
12
Funding: $73.7M
Neural Analytics is addressing the global traumatic brain injury epidemic through data science. The company develops robotically assisted ultrasound system for brain health assessment. The company’s technology integrates ultrasound, robotics and machine learning to empower neurologists with critical information about brain health
Neural Analytics is addressing the global traumatic brain injury epidemic through data science. The company develops robotically assisted ultrasound system for brain health assessment. The company’s technology integrates ultrasound, robotics and machine learning to empower neurologists with critical information about brain health
13
Funding: $42.5M
Cervel Neurotech is a privately held medical device company, pioneering a non-invasive, non-pharmacologic and non-systemic treatment for psychiatric and neurologic illnesses. Cervel Neurotech is pioneering a new approach to an established technology – repetitive transcranial magnetic stimulation (rTMS) – designed to produce better outcomes and a more comfortable treatment for patients.
Cervel Neurotech is a privately held medical device company, pioneering a non-invasive, non-pharmacologic and non-systemic treatment for psychiatric and neurologic illnesses. Cervel Neurotech is pioneering a new approach to an established technology – repetitive transcranial magnetic stimulation (rTMS) – designed to produce better outcomes and a more comfortable treatment for patients.
14
Funding: $41.3M
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
15
Funding: $14.4M
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
16
Cortera Neurotechnologies designs medical devices aimed at revolutionizing the treatment of intractable neurological conditions.
17
VistaraBio is applying their proteostasis technologies for target identification in Parkinson's and other neurodegenerative diseases.